Literature DB >> 29111259

Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study.

Miranda M Fidler1, Sumit Gupta2, Isabelle Soerjomataram3, Jacques Ferlay3, Eva Steliarova-Foucher3, Freddie Bray3.   

Abstract

BACKGROUND: To date, the burden of cancer among young adults has rarely been studied in depth. Our aim was to describe the scale and profile of cancer incidence and mortality worldwide among 20-39 year-olds, highlighting major patterns by age, sex, development level, and geographical region.
METHODS: We did a population-based study to quantify the burden of young adult cancers worldwide. We defined young adult cancers as those occurring between the ages of 20 and 39 years because these individuals will have passed puberty and adolescence, but not yet experienced the effects of hormonal decline, immune response deterioration, or organ dysfunction associated with chronic health conditions. Global, regional, and country-specific (n=184) data estimates of the number of new cancer cases and cancer-associated deaths that occurred in 2012 among young adults were extracted in four 5-year bands from the International Agency for Research on Cancer's GLOBOCAN 2012 for all cancers combined and for 27 major types as defined by the International Classification of Disease, tenth revision. We report the number of new cancer cases and cancer-associated deaths overall and by sex alongside corresponding age-standardised rates (ASR) per 100 000 people per year. We also present results using four levels of the Human Development Index (HDI; low [least developed], medium, high, and very high [most developed]), which is a composite indicator for socioeconomic development comprising life expectancy, education, and gross national income.
FINDINGS: 975 396 new cancer cases and 358 392 cancer-associated deaths occurred among young adults worldwide in 2012, which equated to an ASR of 43·3 new cancer cases per 100 000 people per year and 15·9 cancer-associated deaths per 100 000 people per year. The burden was disproportionally greater among women and the most common cancer types overall in terms of new cases were female breast cancer, cervical cancer, thyroid cancer, leukaemia, and colorectal cancer; in terms of deaths, female breast cancer, liver cancer, leukaemia, and cervical cancer were the main contributors. When assessed by development level and geographical region, the cancer profile varied substantially; generally, the burden of infection-associated cancers was greater in regions under transition. Cancer incidence was elevated in very high-HDI regions compared with low-HDI regions (ASR 64·5 vs 46·2 cancer cases per 100 000 people per year); however, the mortality burden was 3 times higher in low-HDI regions (ASR 25·4 vs 9·2 cancer-associated deaths per 100 000 people per year), reflecting differences in cancer profiles and inferior outcomes.
INTERPRETATION: The global cancer burden among 20-39 year-olds differs from that seen in younger or older ages and varies substantially by age, sex, development level, and geographical region. Although the cancer burden is lower in this age group than that observed in older ages, the societal and economic effects remain great given the major effects of premature morbidity and mortality. Targeted surveillance, prevention, and treatment are needed to reduce the cancer burden in this underserved age group. FUNDING: International Agency for Research on Cancer (IARC) and European Commission's FP-7 Marie Curie Actions-People-COFUND.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products, or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.

Entities:  

Mesh:

Year:  2017        PMID: 29111259     DOI: 10.1016/S1470-2045(17)30677-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  137 in total

1.  Improving recruitment and retention of adolescents and young adults with cancer in randomized controlled clinical trials.

Authors:  Sharron L Docherty; Stacey Crane; Joan E Haase; Sheri L Robb
Journal:  Int J Adolesc Med Health       Date:  2019-04-11

Review 2.  Disrupting gender norms in health systems: making the case for change.

Authors:  Katherine Hay; Lotus McDougal; Valerie Percival; Sarah Henry; Jeni Klugman; Haja Wurie; Joanna Raven; Fortunate Shabalala; Rebecca Fielding-Miller; Arnab Dey; Nabamallika Dehingia; Rosemary Morgan; Yamini Atmavilas; Niranjan Saggurti; Jennifer Yore; Elena Blokhina; Rumana Huque; Edwine Barasa; Nandita Bhan; Chandani Kharel; Jay G Silverman; Anita Raj
Journal:  Lancet       Date:  2019-05-30       Impact factor: 79.321

3.  Thyroid cancer: incidence and mortality trends in China, 2005-2015.

Authors:  Junyi Wang; Fangfang Yu; Yanna Shang; Zhiguang Ping; Li Liu
Journal:  Endocrine       Date:  2020-01-30       Impact factor: 3.633

4.  HLA and KIR Associations of Cervical Neoplasia.

Authors:  Xiao Bao; Aimee L Hanson; Margaret M Madeleine; Sophia S Wang; Stephen M Schwartz; Felicity Newell; Ulrika Pettersson-Kymmer; Kari Hemminki; Sven Tiews; Winfried Steinberg; Janet S Rader; Felipe Castro; Mahboobeh Safaeian; Eduardo L Franco; François Coutlée; Claes Ohlsson; Adrian Cortes; Mhairi Marshall; Pamela Mukhopadhyay; Katie Cremin; Lisa G Johnson; Suzanne M Garland; Sepehr N Tabrizi; Nicolas Wentzensen; Freddy Sitas; Cornelia Trimble; Julian Little; Maggie Cruickshank; Ian H Frazer; Allan Hildesheim; Matthew A Brown; Emma L Duncan; Ying Pu Sun; Paul J Leo
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

5.  Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.

Authors:  Mohamed E Salem; Francesca Battaglin; Richard M Goldberg; Alberto Puccini; Anthony F Shields; David Arguello; W Michael Korn; John L Marshall; Axel Grothey; Heinz-Josef Lenz
Journal:  Oncologist       Date:  2019-12-17

6.  Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer.

Authors:  Tsutomu Namikawa; Nobuko Ishida; Sachi Tsuda; Kazune Fujisawa; Eri Munekage; Jun Iwabu; Masaya Munekage; Sunao Uemura; Shigehiro Tsujii; Takahiko Tamura; Tomoaki Yatabe; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Gastric Cancer       Date:  2018-11-11       Impact factor: 7.370

7.  Pathological Complete Response by S-1 Chemotherapy in Advanced Gastric Cancer.

Authors:  Tsutomu Namikawa; Nobuko Ishida; Sachi Tsuda; Kazune Fujisawa; Eri Munekage; Jun Iwabu; Masaya Munekage; Sunao Uemura; Shigehiro Tsujii; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

8.  Rising Mortality Rate of Cervical Cancer in Younger Women in Urban China.

Authors:  Min Wei; Wei Zhou; Yongyi Bi; Hong Wang; Yu Liu; Zhi-Jiang Zhang
Journal:  J Gen Intern Med       Date:  2018-11-27       Impact factor: 5.128

9.  Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors.

Authors:  Tyler G Ketterl; Karen L Syrjala; Jacqueline Casillas; Linda A Jacobs; Steven C Palmer; Mary S McCabe; Patricia A Ganz; Linda Overholser; Ann Partridge; Emily Jo Rajotte; Abby R Rosenberg; Betsy Risendal; Donald L Rosenstein; Kevin Scott Baker
Journal:  Cancer       Date:  2019-02-01       Impact factor: 6.860

10.  International Trends in the Incidence of Cancer Among Adolescents and Young Adults.

Authors:  Sumit Gupta; Andrew Harper; Yibing Ruan; Ronald Barr; A Lindsay Frazier; Jacques Ferlay; Eva Steliarova-Foucher; Miranda M Fidler-Benaoudia
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.